

الأجسام المضادة للاكسدة  
(OLAB**ntibodies**)  
فى مرض السكرى النوع الأول

رسالة

توطئة للحصول على درجة الماجستير  
فى طب الأطفال

مقدمة من

إنجى صفوت لويس  
بكالوريوس الطب والجراحة

تحت إشراف

أ.د. محمد أبو الأسرار محمد البيومى عفيفى

أستاذ مساعد طب الأطفال

كلية الطب - جامعة عين شمس

د. نزمين حلمى محمود

أستاذ مساعد الباثولوجيا الإكلينيكية والكيميائية

كلية الطب - جامعة عين شمس

د. نيفين جمال أندراوس

مدرس طب الأطفال

كلية الطب - جامعة عين شمس

كلية الطب

جامعة عين شمس

٢٠١٢

**OXIDIZED LOW DENSITY**  
**L-IOPROTEIN ANTIBODIES (OLAB**B**)**  
**IN TYPE I DIABETES MELLITUS**

*Thesis*

Submitted for Partial Fulfillment of the  
Master. Degree in Pediatrics

*Presented By*  
**Engy Safwat Lewis**  
(M.B.B.Ch.)

*Under the Supervision of*

**Dr. Mohamed Abo-El-Asrar Mohamed**

Assistant Professor of Pediatrics  
Faculty of Medicine - Ain Shams University

**Dr. Nermin Helmy Mahmoud**

Assistant Professor of Clinical and Chemical Pathology  
Faculty of Medicine - Ain Shams University

**Dr. Nevine Gamal Andrawes**

Lecturer of Pediatrics  
Faculty of Medicine - Ain Shams University

*Ain Shams University*

*Faculty of Medicine*

2011/2012



First and Foremost thanks are to **ALLAH**, The compassionate and merciful, whose help is the main factor in accomplishing this work.


It is my pleasure to express my deepest thanks and gratitude to *Dr. Mohamed Abo-ElAsrar Mohamed*, Assistant Professor of Pediatrics, Ain Sams University for his great help and support, kind supervision and continuous encouragement. I am truly grateful for him.

I would like also to express my profound thanks and gratitude to *Dr. Mervine Helmy Mahmoud*, Assistant Professor of Clinical and Chemical Pathology, Ain Shams University for her constructive guidance, remarkable effort, and scientific assistance and whatever have been said, is little to express my respect and thanks to her.

I am truly indebted to *Dr. Mervine Gamal Andrawes*, Lecturer of Pediatrics, Ain Shams University for her meticulous supervision, encouragement, unlimited assistance and guidance during this work.

Last but not least, I would like to express my deep thanks and gratitude to all my dear *Patients* hoping them a good health.

Engy Safwat Lewis



*Dedication*

To:

**My Dear Parents**

*Who gave me too much*

*And received too little*

*Engy*

## LIST OF CONTENTS

Title	Page No.
Introduction .....	1
Aim of the work.....	4
<b>Review of literature</b>	
• Diabetes mellitus.....	<b>Error! Bookmark not defined.</b> <a href="#">5</a>
• Oxidized low density lipoprotein antibodies .....	<a href="#">56</a>
Subject and methods .....	81
Results .....	89
Discussion.....	116
Summary.....	128
Recommendation .....	132
References .....	134
Arabic summary .....	—



<u>Table (1): Etiologic classification of diabetes mellitus</u>	6
<u>Table (2): Characteristic features of type 1 compared with type 2 diabetes in young people</u>	7
<u>Table (3): The clinical and biological characteristic of the different subtypes of type 1 diabetes</u>	8
<u>Table (4): Criteria for the diagnosis of diabetes mellitus</u>	15
<u>Table (5): Complications of Diabetes</u>	16
<u>Table (6): The early changes are only detectable on careful clinical or laboratory examination</u>	20
<u>Table (7): Classification and features of diabetic retinopathy</u>	20
<u>Table (8): Methods for prevention of type 1 diabetes</u>	23
<u>Table (9): Factors determining the glycemie response to acute exercise in type 1 DM patients</u>	33
<u>Table (10): Types of insulin currently available</u>	34
<u>Table (11): Indications for the use of the pump in Children of different ages</u>	43
<u>Table (12): Comparison between different types of insulin</u>	56
<u>Table (13): Composition of the lipoproteins in plasma of humans</u>	67
<u>Table (14): Age of the studied groups</u>	94
<u>Table (15): Sex distribution between studied groups</u>	95
<u>Table (16): Comparison between the studied groups according to the age of the patients</u>	96
<u>Table (17): Comparison between the three studied groups according to the anthropometric measures</u>	97

**Table (18):** Comparison between the three studied groups according to the laboratory findings..... 98

LIST OF TABLES (CONT...)

---

<u><b>Tab. No.</b></u> .....	<u><b>Title</b></u>
------------------------------	---------------------

---

**Table (19):** Comparison between the good metabolic control group and bad metabolic control group according to anthropometric measurements ..... 102

**Table (20):** Comparison between the good metabolic control group and bad metabolic control group according to laboratory findings ..... 103

**Table (21):** Comparison between the good control group and the healthy group according to studied parameters..... 105

**Table (22):** Comparison between the bad control group and the healthy group according to studied parameters..... 107

**Table (23):** Correlation between LDL antibodies and the studied parameters in the three groups..... 109

**Formatted:** Font: (Default) Times New Roman, 12 pt, Complex Script Font: Times New Roman, 12 pt

**Formatted:** Font: (Default) Times New Roman, Complex Script Font: Times New Roman

**Formatted:** Font: (Default) Times New Roman, 12 pt, Complex Script Font: Times New Roman, 12 pt



# LIST OF FIGURES

Fig. No.	Title	Page No.
<b>Figure (1):</b>	<u>Pathogenesis of type 1 diabetes.....</u>	14
<b>Figure (2):</b>	<u>Triggering of beta-cell autoimmunity.....</u>	17
<b>Figure (3):</b>	<u>The pathogenesis of islet cell destruction .....</u>	22
<b>Figure (4):</b>	<u>Natural history of type 1a diabetes .....</u>	24
<b>Figure (5):</b>	<u>Diabetic background retinopathy .....</u>	33
<b>Figure (6):</b>	<u>The multifactorial pathogenesis of diabetic neuropathy.....</u>	37
<b>Figure (7):</b>	<u>Contributing factors of diabetic management.....</u>	40
<b>Figure (8):</b>	<u>Syringe and needle .....</u>	44
<b>Figure (9):</b>	<u>Disposable insulin pen.....</u>	44
<b>Figure (10):</b>	<u>Refillable insulin pen.....</u>	45
<b>Figure (11):</b>	<u>Disposable insulin device with large dial .....</u>	45
<b>Figure (12):</b>	<u>Insulin pump, showing an infusion set loaded into spring- Loaded insertion device .....</u>	46
<b>Figure (13):</b>	<u>Insulin pump attached to its user with an infusion set .....</u>	47
<b>Figure (14):</b>	<u>Islet cell transplantation .....</u>	49
<b>Figure (15):</b>	<u>The medical equipment approach to an artificial pancreas .....</u>	52
<b>Figure (16):</b>	<u>The Bio-artificial pancreas.....</u>	53
<b>Figure (17):</b>	<u>Gene therapy using an adenovirus vector .....</u>	54
<b>Figure (18):</b>	<u>Transport of cholesterol between the tissues in humans .....</u>	61
<b>Figure (19):</b>	<u>Summary of the main events of lipid peroxidation and foam cell formation.....</u>	76

**Formatted:** Justify Low, Indent: Before: 0 cm, Hanging: 2.59 cm, After: 2.22 cm, Space Before: 6 pt, Tab stops: 12.7 cm, Right,Leader: ... + Not at 12.68 cm

**Formatted:** Font: Bold, Complex Script Font: Bold

## LIST OF FIGURES (CONT...)

<u>Fig. No.</u>	<u>Title</u>	<u>Page No.</u>
<u>Figure (20):</u>	<u>Sex distribution between the three studied groups. ....</u>	<u>102</u>
<u>Figure (21):</u>	<u>Comparison between the studied groups according to the age of the patients. ....</u>	<u>103</u>
<u>Figure (22):</u>	<u>Comparison between the three studied groups according to the anthropometric measures. ....</u>	<u>104</u>
<u>Figure (23):</u>	<u>Comparison between the three studied groups according to Hb and HbA1c. ....</u>	<u>106</u>
<u>Figure (24):</u>	<u>Comparison between the three studied groups according to TG, TC and OxLDL Ab. ....</u>	<u>107</u>
<u>Figure (25):</u>	<u>Comparison between the three studied groups according to LDL and HDL. ....</u>	<u>107</u>
<u>Figure (26):</u>	<u>Comparison between the good metabolic control group and bad metabolic control group according to anthropometric measurements. ....</u>	<u>109</u>
<u>Figure (27):</u>	<u>Comparison between the group I and group II according to PLT, TG, HDL, OXLDL antibodies. ....</u>	<u>110</u>
<u>Figure (28):</u>	<u>Correlation between OxLDL Ab and duration in group I. ....</u>	<u>112</u>
<u>Figure (29):</u>	<u>Correlation between OxLDL Ab and duration in group II. ....</u>	<u>112</u>
<u>Figure (30):</u>	<u>Correlation between HbA1C and OXLDL in group I. ....</u>	<u>113</u>
<u>Figure (31):</u>	<u>Correlation between HbA1C and OXLDL in the good control group. ....</u>	<u>113</u>
<u>Figure (32):</u>	<u>OxLDL Ab levels in group I. ....</u>	<u>114</u>

Formatted: After: 0 cm

Formatted: Font: 13 pt, Complex Script Font: 13 pt

Formatted: Justify Low, Indent: Before: 0 cm, Hanging: 2.59 cm, After: 2.22 cm, Space Before: 6 pt, Tab stops: 12.7 cm, Right, Leader: ... + Not at 12.68 cm

Formatted: Font: Bold, Complex Script Font: Bold

Formatted: Font: Bold, Complex Script Font: Bold

Formatted: Font: Bold, Complex Script Font: Bold

Formatted: Font: Bold, Complex Script Font: Bold

Formatted: Font: Bold, Complex Script Font: Bold

Formatted: Condensed by 0.2 pt

<u>Figure (1):</u> — Progression from genetic susceptibility to overt type I diabetes.....	11
<u>Figure (2):</u> — A possible mechanism for the immune destruction of pancreatic B-cells in IDDM.....	13
<u>Figure (3):</u> — Clinical course of diabetic nephropathy.....	21
<u>Figure (4):</u> — Insulin delivery devices.....	35
<u>Figure (5):</u> — How Islet Cell Transplant surgery works.....	37
<u>Figure (6):</u> — The artificial pancreas.....	38
<u>Figure (7):</u> — The Exubera inhaler.....	40
<u>Figure (8):</u> — The catheter at the end of the insulin pump is inserted through a needle into the abdominal fat of a person with diabetes.....	42
<u>Figure (9):</u> — An image of an insulin pump.....	58
<u>Figure (10):</u> — Another example of insulin pumps of Medtronic.....	58
<u>Figure (11):</u> — An image shows a miniature size of in vivo blood glucose sensor that is being developed.....	59
<u>Figure (12):</u> — Transport of cholesterol between the tissues in humans.....	65
<u>Figure (13):</u> — Summary of the main events of lipid peroxidation and foam cell formation. The LDL particle is not only rapidly uptaken by macrophages via the scavenger receptor, but has also antigenic properties.....	81
<u>Figure (14):</u> — Sex distribution between studied groups.....	95
<u>Figure (15):</u> — Comparison between the studied groups according to the age of the patients.....	96

## **LIST OF FIGURES (CONT...)**

<b>Fig. No.</b> .....	<b>Title</b>
<u>Figure (16):</u> — Comparison between the three studied groups according to the anthropometric measures.....	97

<b>Figure (17):</b> Comparison between the three studied groups according to Hb, Duration of DM, WBC.....	99
<b>Figure (18):</b> Comparison between the three studied groups according to PLT, RBG, TG, T. cholesterol and OXLDL.....	99
<b>Figure (19):</b> Comparison between the three studied groups according to T3, T4 and C peptide.....	100
<b>Figure (20):</b> Comparison between the three studied groups according to T3, T4 and C peptide.....	100
<b>Figure (21):</b> Comparison between the good metabolic control group and bad metabolic control group according to anthropometric measurements.....	102
<b>Figure (22):</b> Comparison between the good metabolic control group and bad metabolic control group according to Hb, WBC, HbA1c, T3, T4 and C peptide.....	104
<b>Figure (23):</b> Comparison between the good metabolic control group and bad metabolic control group according to PLT, TG, HDL, OXLDL antibodies.....	104
<b>Figure (24):</b> Comparison between the good control group and the healthy group according to Ht, BMI HB.....	106

## **LIST OF FIGURES (CONT...)**

<b>Fig. No.</b> .....	<b>Title</b>
<b>Figure (25):</b> Comparison between the good control group and the healthy group according to PLT, RBG, TG, T. cholesterol and OXLDL.....	106
<b>Figure (26):</b> Comparison between the bad control group and the healthy group according to Ht, BMI and Hb.....	108

<u>Figure (27): Comparison between the bad control group and the healthy group according to BG, TG, T. cholesterol and OXLDL antibodies.....</u>	<u>108</u>
<u>Figure (28): Correlation between HbA1C and OXLDL in the bad control group.....</u>	<u>110</u>
<u>Figure (29): Correlation between HbA1C and OXLDL in the good control group.....</u>	<u>111</u>

# LIST OF ABBREVIATIONS

Abbrev.	Full term
<del><b><u>α</u>AAT</b></del>	Alpha 1 antitrypsin
<b>AGE</b>	Advanced glycation protein
<del><b>apo E<sub>1</sub></b></del>	Apolipoprotein E1
<b>BCG</b>	Bacillus calmette Guerin
<b>BG</b>	Blood glucose
<b>BM</b>	Basement membrane
<b>BMI</b>	Body mass index
<b>CAD</b>	<del>Coronary artery</del> Coronary artery disease
<b>CBC</b>	Complete blood count
<b>CIM</b>	Carotid <del>intima</del> intima thickness
<b>CM</b>	Chylomicrons
<b>CSII</b>	Continuous subcutaneous insulin infusion
<b>CVD</b>	Cardiovascular disease
<b>DKA</b>	Diabetic ketoacidosis
<b>DM</b>	Diabetes mellitus
<b>DPT1</b>	Diabetes prevention trial <u>1</u>
<del><b>DSDS</b></del>	<del>Distal symmetrical polyneuropathies</del>
<b>DSPS</b>	Distal symmetrical polyneuropathies
<b>ER</b>	Emergency
<b>FDA</b>	Food and Drug Administration
<b>GLA</b>	Gamma linolenic acid
<del><b>HbB</b></del>	Hemoglobin
<b>HbA1c</b>	Glycated hemoglobin
<b>HDL</b>	High density lipoprotein

Formatted: Spanish (International Sort)

Formatted: Spanish (International Sort), Subscript

Formatted: Spanish (International Sort)

Formatted: Line spacing: single

## LIST OF ABBREVIATIONS (CONT...)

Abbrev.	Full term
HLA	Human leucocyte antigen
IC	Immune complexes <del>LDL</del> <del>LOW density LIPOPROTIEN</del>
ICA	Islet cell antibodies
IDDM	<del>Indepentan</del> <u>Insulin dependent</u> diabetes mellitus
IDL	Intermediate density lipoprotein
Ig M	Immunoglobulin M
IgG	Immunoglobulin G
IV	Intravenous
IVIG	Intravenous immunoglobulin
<u>LP(LP (a))</u>	<u>Lipoprotein a</u> <del>Lipoprotein a</del>
M	Mean
MHC	Major histocompatibility complex
MNT	Medical nutrition therapy
<del>MNT</del>	<del>Medical nutrition therapy</del>
MODY	Maturity onset diabetes of the youth
NO	Nitric oxide
OxLDL	<u>Oxidized low density lipoprotein</u>
	<del>Antibodies low density lipoprotein antibodies</del>
OxLDL <u>Ab</u>	Oxidized LDL <u>antibodies</u>
PUFAs	Polyunsaturated fatty acids
r AVV	Recombinant adeno associated virus vector
SD	<u>Standard</u> <del>Standard</del> deviation
<del>SDS</del>	Stable dimmers
SDS	Standard deviation score

Formatted: French (France)

Formatted: French (France)